CAR-T cell therapy research

This study tracks the temporal changes in the tumor microenvironment after nanobody-based CAR-T therapy, revealing dynamic gene expression shifts and identifying potential therapeutic targets.

This paper develops a pharmacologically controlled system for regulating CAR T cell function using estrogen receptor-based degron domains and FDA-approved compounds.

This study shows that engineered NKG2C+ NK-like T cells have better antitumor effects and lower cytokine release syndrome risk than conventional CAR-T and CAR-NK cells.

The paper validates and analyzes 12,000 AI-designed CAR-T binders from a global competition, identifying successful designs and factors improving their performance.

This study identifies tumor-intrinsic stress states as modulators of CAR T cell therapy response in pancreatic cancer using CRISPR screens and single-cell genomics.

This study shows that blocking TGFβ signaling in TCR-engineered T cells and enhancing antigen processing in tumor cells improves their therapeutic effectiveness against pancreatic ductal adenocarcinoma.

This study shows obesity impairs B7-H3.CAR-T cell antitumor activity and memory formation in TNBC by altering cytokine profiles and metabolic function.

This paper develops a CRISPRa-based method to identify genes enhancing CAR T cell survival in different tumor environments.

The paper introduces mpTCRai, a deep learning framework that maps structural perturbations to energetic changes in TCRs, enabling precise and safe TCR design for immunotherapy.

This study develops meditope-enabled CARs to improve T cell functionality and address tumor heterogeneity in CAR therapy.

This study develops a tunable OR-gated CAR system for AML treatment that effectively targets multiple antigens with reduced engineering complexity and minimized off-target toxicity.

The paper develops a mathematical model and Bayesian framework to evaluate CAR T-cell efficacy against AML, revealing antigen-specific resistance mechanisms.

This paper demonstrates a personalized SNAP-TIL therapy platform that improves TIL efficacy by enriching them with neoantigen-reactive T-cells, achieving high CD3+ cell content and significant tumor growth inhibition in preclinical models.

The paper uses Sleeping Beauty mutagenesis to identify BACH2 and other genes that enhance CD8+ T cell persistence and function under chronic antigen stimulation, improving engineered T cell therapies.

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

This study develops a switchable CAR-T cell system that allows precise control of CAR activity, reducing toxicity and exhaustion while maintaining therapeutic efficacy.

This paper introduces a method to enhance T cell therapy by using a CAR targeting uPAR to eliminate dysfunctional T cells through directed fratricide.

This paper develops a delay differential equation model for CAR-T cell kinetics, showing it better fits longitudinal data and supports delayed conversion from effector to memory cells.

This paper develops a novel CAR-M targeting GPC3 with IFN-gamma and SIRPECD to enhance anti-tumor activity in hepatocellular carcinoma.

This paper develops a 3D tumor microenvironment model to predict CAR-T therapy outcomes in solid tumors, finding that collagen density and metabolic competition are key determinants of efficacy.

This study shows dendritic cells enhance CAR T cell persistence in irradiated tumors by antigen-dressing and stimulating CAR T cells through chimeric receptors.

The paper applies T-cell receptor sequencing and epitope annotation tools to quality control and immune monitoring of TIL products by identifying tumor-specific clones and screening for off-cancer reactivity.

This study shows that low-strength type I interferon signaling enhances CAR T-cell efficacy against B-cell lymphoma and leukemia without causing in vivo toxicity.

This study develops fully human B7-H3 CAR T cells using phage display, showing improved antitumor activity and reduced immune response in xenograft models.

This study designs PD-1-targeting CAR-T-cells to reduce the HIV reservoir by depleting specific T-cell subpopulations in HIV-infected humanized mice.

This study shows that inhibiting cathepsin B prevents CAR T cell fratricide and exhaustion by blocking trogocytosis, improving CAR T cell persistence and anti-tumor activity.

This study edits Cyclophilin A's C-terminus using CRISPR/Cas9 to create cell therapies resistant to cyclosporine and voclosporin, preserving function in immune suppression settings.

This study develops GrB-CAR T cells targeting mHSP70 to eliminate CTCs and inhibit metastasis in solid tumors.